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Abstract Therehasbeenaworldwideincreaseinmultiple drug-resistanttuberculosis (MDR-TB)whichhasinthepast
been associatedwith a poor prognosis.In the U.K., about half of the cases live in the London area andwehave setoutto
obtain further information on their treatment and outcome.We examined the risk factors, drug resistance, drug treat-
ment, sputumconversion, and outcome inpatientswith MDR-TB atthree hospitals in South London and diagnosed dur-
ing the period June1995^ January1999.Human Immunode¢ciency Virus (HIV)-positive patients were excluded.There
were 760 patients resident in Lambeth, Southwark and Lewisham Health Authority (LSLHA) whowere noti¢ed as tu-
berculosis (TB) during the time period andwhowere of negative or unknown HIV status. (The population of LSLHA is
approx.750 000.) Therewasatotalof13 patientswithMDR-TB, knownorpresumedtobeHIVnegative.Theirmedianage
was 28 years (range15^53); nine (69%) were born outside the U.K. and11had pulmonary disease; they had organisms
resistant to a median of two ¢rst-line drugs (range 2^4) and to a median of four of all drugs tested (range 2^10).
They received treatment with a median of six drugs (range 3^9). Eight were followed up for at least 3 years
(range 3^6) after the completion of treatment; at their last assessment none had features of active TB and all were
sputum negative (smear and culture). Two returned to their countries of origin during treatment; they were sputum
negative at that time.Two patients are well and continue on treatment in the U.K.One patient (known HIV negative)
died following treatment failure. In conclusion, we obtained disease-free survival in eight cases of MDR-TB, known or
presumed to be HIV negative and followed up for 3 years or more.The prognosis for patients treated at specialised
centres is good (and better than is generally believed).We describe a new protocol for the detection andmanagement
of MDR-TB.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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The termmultiple drug-resistant tuberculosis (MDR-TB)
indicates thepresence of a strain ofMycobacteriumtuber-
culosis (MTB) resistant to both rifampicin and isoniazid
(the two most important drugs for the treatment of
TB) with or without resistance to other drugs. Over
the last 20 years, there has been a serious worldwide in-
crease in the total number of cases (1).
During the NewYorkTB epidemic of the early 1990s,
the percentage of TB patients with MDR-TB reached a
¢gure of no less than 19% (2) and there were fears of a
similar occurrence in the U.K. However, the prevalence
of MDR-TB in the U.K. during 1994^1998 has remained
steady at about 1.4% (3,4). About half were living in the
London area (3) where the prevalence of MDR-TB was
2.3% (CI: 1.8^2.8), signi¢cantly greater than the rate forReceived 5 February 2002, accepted in revised form 29 May 2002.
Correspondence should be addressed to:Dr D.C.S.Hutchison,
Department of Respiratory Medicine, King’s College Hospital, London
SE5 9RS,U.K.Fax: +44 20 73 46 35 89the remainder of the U.K. (1.0%: CI: 0.8^1.3). Few were
proven to be infectedwith the human immunode¢ciency
virus (HIV), though there has been undernoti¢cation of
TB in this group (5).
MDR-TB is a much feared disorder and even without
HIV infection has been associated with a poor outcome
(6) though a better prognosis has beenmore recently re-
ported (7). Atpresent, there is limitedknowledge of the
management of MDR-TB in the U.K. and of the outcome
in terms of cure and mortality.We have therefore stu-
died the management of MDR-TB patients in TB clinics
in Lambeth, Southwark and LewishamHealth Authority
(LSLHA) over a period of 312 years and have
developedwhat we believe to be improvedmanagement
guidelines.
PATIENTSANDMETHODS
We have examined the records of all 13 patients with
MDR-TB who were HIV negative or thought likely to
be so, who had attended theTB clinics of Guy’s, King’s
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asTB to LSLHA between 1 June 1995 and 1 January 1999
(3.6 years).We obtained evidence on the drug-resistance
pattern, previous and current drug treatment, country
of origin, risk factors and the eventual outcome. HIV
tests were not routinely performed but, for this study,
known HIV-positive cases were excluded.
Microscopy and culture were performed at the Public
Health Laboratory Service (PHLS) Mycobacterium Re-
ference Unit (MRU), King’s College Hospital (Dulwich)
or the Department of Microbiology, St Thomas’ Hospi-
tal. Drug susceptibility was determined at the PHLS
MRU or the Royal Brompton Hospital. Primary speci-
menswere cultured on Lowenstein^Jensen and/or liquid
culture media (OrganonTeknika, Cambridge, U.K.). Cul-
tures from all the MDR-TB cases were identi¢ed as MTB
using DNA hybridisation analysis (Geneprobe, San Die-
go, U.S.A.) and biochemical and microscopical growth
characteristics. Drug susceptibility was assessed using
resistance ratio on solidmedia or a modi¢ed proportion
method in the Bactec 460 system.
RESULTS
There were 760 patients of negative or unknown HIV
status, resident in LSLHA (population approx. 750 000),TABLE. 1. MDR-TB follow-up group.Patientdetails, drugresista
Patient
number
Age Countryof
origin
Risk factors Drugresistan
First line Secon
1 15 Somalia a, d 1.H S
2.RH S
2 33 Somalia a, b 1.RHE SP
3 20 U.K. b, d 1.H S
2.RH S
4 39 U.K. b, c 1.Nil
2.RH
5 22 Vietnam e 1.RH SC
6 22 Sierra Leone a 1.RH S
2.RHZ S
7 36 U.K. b, c, d 1.H
2.RH CL
8 28 Sierra Leone Nil 1.RH CYC CL
Note: AllhadpulmonaryTB exceptcase 5 (chestwall abscess)
Risk factors: (a) Previous treatment, (b) poor compliance, (c) alco
e¡ects.
Boldnumerals: initial and subsequentdrug-resistance patterns a
*Overall duration: from ¢rstto lastdayoftreatment.
Key:R, rifampicin;H, isoniazid; Z, pyrazinamide;E, ethambutol,
thromycin;CLO, clofazimine;CYC, cycloserine;ETH, ethionamidwho were noti¢ed asTB during the observation period.
These include the13MDR-TB patients (1.7%: 95%CI: 0.8^
2.8) in this study (Tables1and 2). Five were known to be
HIVnegative.HIV statuswas not established in the other
eight, who seem unlikely to have been HIV positive, in
view of their clinical course and length of disease-free
survival. Seven MDR-TB HIV positive patients identi¢ed
during the same time period are not considered in this
study.
The 13 selected MDR-TB cases (Tables 1 and 2) had a
median age of 28 years (range15^53). All had pulmonary
disease except two (chest-wall abscess; lymph nodeTB).
Their countries of origin were: U.K., 4 cases: Somalia, 3;
Sierra Leone, 3; Vietnam, Ghana and Portugal, 1 each.
Nine patients received ‘directly observed therapy’
(DOT) during part of their course of treatment; other-
wise, they were managed by close monitoring, frequent
follow-up and home visits from theTB nursing team.
First-line drugs are de¢ned here as: rifampicin, isonia-
zid, pyrazinamide and ethambutol. All others are consid-
ered as second-line drugs. In eight patients, drug
resistance increased during the course of treatment
(Fig.1).
(InTables1and 2, the Bold numerals indicate:1The in-
itial drug resistances and treatment regimens. 2 and 3
The main changes in drug resistance and resulting
changes in treatment. For example, inTable 1, patient 1,nce and treatment
ce Treatment
d line Drugs and changes Overall duration (months)*
1.RHZ (E added) 18
2.ZEOFETH
AS 1.ZEOFPRO 18
1.R Z 12
2.ZE
1.RHZ 18
2.ZEPROCIP
IP 1.EZ CLAR 24
2.ECLOPRO
1.RHZ 18
2.ECIP ETH
1.RHZE 15
AR 2. SZE
AR CLO 1.RHZ 9
2.ZECIP S
and case 8 (cervicalnodeTB).
hol/drug abuse, (d) initial isoniazid resistance, (e) hepatic side-
ndresulting treatmentregimens (and see text).
S, streptomycin; CIP, cipro£oxacin;OF, o£oxacin; CLAR, clari-
ep;PRO, prothionamide,PAS, para-aminosalicylic acid.
FIG 1. Development of resistance patterns in isolates from 13
MDR-TB patients. Initially, three patients had fully sensitive or-
ganisms and three had isoniazid resistance only. Pyrazinamide
or ethambutol resistancewas unusual.Key:R, rifampicin;H, iso-
niazid; Z, pyrazinamide; E, ethambutol; S, streptomycin; CIP, ci-
pro£oxacin; CLA, clarithromycin; CY, cycloserine; AM,
amikacin;CLO, clofazimine;PAS, para-aminosalicylic acid.
TABLE 2 MDR-TB non-follow-up group.Patientdetails, drugresistance and treatment
Patient
number
Age Countryof
origin
Risk factors
for MDR-TB
Drugresistance Treatment
First line Second line Drugs and changes Overall duration (months)*
9 25 Ghana a 1.RH S 1.RHZE 6 (Lostto follow-up)
2.RHZ S 2.ZECIP
3.ECIP PROCLAR
10 53 U.K. a 1.RH CLAR 1.ZE SCIP CLARPROPAS 18
2.ZECIP PROCLAR
11 40 Portugal a 1.RHE CLAR 1.ZS CIP PAS 6 (Lostto follow-up)
12 35 Somalia Nil 1.Nil F 1.RHZE 18
2.RH CLO 2.ECIP CLARCYCPASPRO S
3.RH CIP CLO 3.ECLARCYCPROPAS
13 (DIED) 20 Sierra Leone b 1.Nil F 1.RHZ 30
2.RH F 2.EZCIP S
3.RHEZ CAP 3.E ETHLEVPAS
CIP CLO PRO M.Vaccae
CYC S
Note: AllhadpulmonaryTB.
Risk factors: (a) Previous treatment, (b) poorcompliance.
Boldnumerals: initial and subsequentdrug-resistance patterns andresulting treatmentregimens (and see text).
*Overall duration: from ¢rstto lastdayoftreatment.
Key:R, rifampicin:H, isoniazid;Z, pyrazinamide;E, ethambutol;S, streptomycin;CIP, cipro£oxacin;CLAR, clarithromycin;CLO,
clofazimine;ETH, ethionamide;PRO, prothionamide;CYC, cycloserine;LEV, levo£oxacin.
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ismwas found to be resistant to isoniazid and treatment
was started with the three drugs shown. Numeral 2 in-
dicates the subsequent development of rifampicin resis-
tance when treatment was changed to the four drugs
shown, namely pyrazinamide, ethambutol, o£oxacin and
ethionamide.)
All patients but three had at least one of the following
risk factors:
(a) Previous treatment forTB: six patients (four born
and treatedoutside theU.K., threewith inadequate drug
regimens).(b) Isoniazid resistance without rifampicin resistance:
three patients.
(c) Poor compliance: four patients.
(d) Drug and/or alcohol abuse: two patients.
Patientswith 3 ormore years follow-up after
treatment (Table1)
Eight patients were followed up for 3 years or more
(range 3^6) after the end of drug treatment.Their ¢nal
resistance patternwas as follows:
Resistance to all ¢rst and second line drugs.The patients
had organisms resistant to a median of three drugs
(range 2^6).
Resistance to ¢rst-line drugs. Six patients: resis-
tance to rifampicin and isoniazid only.One patient: resis-
tance to rifampicin, isoniazid and pyrazinamide.
One patient: resistance to rifampicin, isoniazid and
ethambutol.
Resistance to second-line drugs. In ¢ve of the eight pa-
tients, there was resistance to streptomycin, in two
combined with resistance to other second-line drugs
(Table1).
Use ofchemotherapy.Themedian number of drugs used
in the eight follow-up patients after diagnosis of MDR-TB
was 3 (range 2^4).Nine drugs were used in all: pyrazina-
mide, ethambutol, streptomycin, cipro£oxacin, o£oxa-
cin, clarithromycin, clofazimine, prothionamide and
ethionamide. The median overall duration of treatment
68 RESPIRATORYMEDICINEwas18 months (range 9^24) (Tables1 and 2). No patient
had features of active disease at their last assessment
and the six pulmonary caseswere sputum smear and cul-
ture negative.
Hepatotoxicity.One patient had drug-associated hepa-
totoxicity with no other risk factors.The organismwas
resistant to rifampicin, isoniazid, streptomycin and ci-
pro£oxacin and there was hepatic intolerance to pyrazi-
namide and clarithromycin. The patient was eventually
treated with three drugs only (ethambutol, prothiona-
mide and clofazimine) with no recurrence 4 years after
the end of 2 years of treatment.
Patientswithout long-term follow up
(Table 2)
One patient has recently completed 18 months drug
therapy and one has completed 2 years of therapy. Both
arewell andregarded as disease free.Tworeceivedonly 6
months therapybefore returning to their country of ori-
gin; they had improved clinically andwere sputum smear
negative.
Mortality
There was one death in a 20-year-old HIV-negative fe-
male. The organism was initially fully sensitive, but the
patient was lost to follow-up for a period and on re-at-
tendance had developed MDR-TB. Shewas subsequently
treated entirely in hospital, but died following treatment
failure 30months later. Sheremained sputumculture po-
sitive throughout and in the later stages the organism
became resistant to all four ¢rst-line drugs and to six
second-line drugs (Table 2).
DISCUSSION
In spite of the worldwide increase in MDR-TB (1), there
has been no repetition of the NewYork epidemic (2) in
the U.K. and the prevalence of MDR-TB in the U.K. dur-
ing the years 1994^1998 has remained steady at about
1.4%, the large majority being of negative or unknown
HIV status (3,4). In other countries of Western Europe
(8^11), the prevalence rates are similar. The percentage
of TB patientswithMDR-TB at thepeakof theNewYork
epidemic was as high as 19%, which was associated with
much higher rates of homelessness and HIV infection
than are found in London.
MDR-TB iswidely regarded as having a poor prognosis
(6) though there is very limited information on the man-
agement and outcome ofMDR-TB in the U.K. About half
of theMDR-TB cases in theU.K. are found in the London
area (3) and even though our case numbers are small, we
believe our district to be representative of the manage-
ment problems likely to arise in large urban areas.In summary, a total of 760 patients with negative or
unknown HIV status and resident in LSLHAwere noti-
¢ed asTB cases during our 3.6-year observation period.
Among this group, we identi¢ed 13 patients with MDR-
TB (1.7%: CI: 0.8^2.8) who were either known to be
HIV negative or on clinical grounds seemed likely to be
so.Therewas one death fromMDR-TB among the13 pa-
tients (7.7%; 95%CI: 0.2^36.0). (Thepopulation ofLSLHA
in1998 was estimated at 750 000 and the overall TB no-
ti¢cation rate at 31per100 000).
Risk factors
The main treatment errors resulting in MDR-TB were
previously found to be (12): (a) addition of a single drug
to a failing regimen, (b) inadequate primary regimen, (c)
failure to recognise drugresistance and (d) failure to deal
with non-compliance. We con¢rmed in this study that
the most powerful predictor of MDR-TB, was a history
of past treatment, which was usually accompanied by an
inadequate drug regimen (13,14).
Nine of our patients with MDR-TBwere born outside
theU.K., three reporting treatment forTB in their coun-
tryof origin for nomore than 2months.Poor compliance
and alcohol or drug abusewere the othermajor risk fac-
tors. Three MDR-TB patients had isolates initially resis-
tant to isoniazid alone; the administration of rifampicin
with pyrazinamide (as triple therapy) did not appear to
prevent the subsequent emergence of rifampicin resis-
tance.
Outcome andmanagement
The management of patients with MDR-TB presents
many di⁄culties; however, our eight cases with 3^6
years of follow-up after the end of treatmentmade good
clinical progress and appear to be cured.Resistance was
limited to a maximum of three ¢rst-line drugs and three
second-line drugs, so that e¡ective agents such as the
£uoroquinolones and prothionamide remained useful.
Our cases had isolates resistant to a median of three
drugs, in contrast to the Denver study (6) where resis-
tance to a median of six drugs was reported, with a cor-
respondingly high mortality. Better results were
reported in later studies and the number of drugs to
which themicro-organisms are resistant has a strong in-
£uence on the outcome (7,15,16).
Recommendeddrug regimens
The British Thoracic Society Guidelines (17) state that
treatment of MDR-TB ‘should start with ¢ve or more
drugs towhich the organism is, or is likely to be, suscep-
tible and continued until sputum cultures have proved
negative.Treatmentmust thenbe continuedwith at least
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tro testing for a minimum of 9 further months and per-
haps up to and beyond 24 months’. The Guidelines
further recommend DOT for all cases of MDR-TB; this
implies DOT daily (with an additional burden on health-
care workers) since there are no proven three times
weekly regimens for MDR-TB.
Iseman (13,18) recommended, for MDR-TB, the admin-
istration of pyrazinamide, ethambutol, a £uoroquinolone
and an aminoglycoside and, with further resistance to
¢rst-line drugs, at least two other e¡ective drugs to be
chosen from ethionamide, cycloserine, capreomycin,
PAS or amoxicillin-clavulate.
Drug susceptibility testing
It is obvious that MDR-TB patients are unlikely to re-
spond to the standard regimen for drug-sensitiveTB (19)
and thatpersistencewith thiswill simply amplify the pro-
blem by causing direct transmission of resistant organ-
isms to new cases (20). In the U.K., where drug
susceptibility testing is available throughout the country,
individualised drug regimens should always be used and
the underlying reasons for any failure of initial therapy
shouldbe identi¢ed and corrected.Eventually, one hopes
that drug susceptibility testing will be available for all
MTB isolates worldwide (21). The U.K. and similar Wes-
tern European states currently have low MDR-TB rates
and these countries should support, even if self-interest
were the only motive, drug susceptibility testing and
treatment of MDR-TB in those undeveloped areas in
whichmanymigrants originate.
Recommendations for detection and
management of MDR-TB
Our study would lend support to the following addi-
tional steps for the detection andmanagement of MDR-
TB in the U.K.
Ascertain history of previous treatment forTB
Themost important risk factor for MDR-TB is a history
of previous treatment for TB. Identi¢cation of speci¢c
drugsbynamemaynotbepossible, but a historyof urine
colour change (suggesting rifampicin) or of a series of in-
jections (suggesting streptomycin) would be valuable in-
formation. The patients can also be shown pictures or
actual examples of the drugs. A non-standard regimen,
particularly if curtailed or unsupervised, should
raise strong suspicions and the presence of MDR-TB
should be assumed until proved otherwise. If there is
pulmonary disease, isolation in a negative pressure facil-
ity should be considered at this stage and thepatient should certainlybe kept apart from the immuno-
compromised.
Test for the presence of MTB and for rifampicin resistance
Sputum or othermaterial can be tested for MTB and for
rifampicin resistance by molecular ampli¢cation techni-
ques and a result obtained in 3^4 days (22); the speci¢-
city and sensitivity are high in sputum-positive samples
though sensitivity is low when sputum is smear negative.
The demonstration of rifampicin resistance is predictive
of MDR-TB in over 90% of cases (22).Transfer to a spe-
cialised centre with negative pressure isolation facilities
is strongly advised at this stage.
Management aftercon¢rmation of rifampicin resistance
and while awaiting further sensitivity tests
The sensitivity pattern to other ¢rst- and second-line
drugs may take 2^4 weeks to establish and may reveal
further drug resistance.While waiting for this report, a
sputum-positive patient should be treated with at least
¢ve drugs. Rifampicin, isoniazid, pyrazinamide and
ethambutol should still be included at this stage with a
£uoroquinolone and prothionamide. (Even if rifampicin-
resistantmutations have been detected, a proportion of
the bacterial load may remain sensitive to this drug.)
Some recommend an injectable drug such as streptomy-
cin at this stage, though six of our patients had isolates
resistant to this drug onpresentation. In anHIV-negative
patient without pulmonary disease or serious symp-
toms, treatment can reasonably bewithheld until the re-
sistance pattern is known.
Management when full sensitivity pattern is known and
MDR-TB con¢rmed
At this stage, prescribing can be done with more con¢-
dence. A minimum of three or four e¡ective drugs
shouldbe chosen, initially from the ¢rst-line drugs which
remain available and then, in order, from an aminoglyco-
side, a £uoroquinolone, prothionamide (or ethionamide),
capreomycin, cycloserine and para-aminosalicylic acid;
clarithromycin has low activity against MTB but is
useful in preventing further resistance. At present, we
recommend that this regimen should continue for a
minimum of 18 months, though some of our patients
were apparently cured after treatment for a shorter
period.
Further supervision
After the patient’s discharge from hospital, maintenance
of the complex drug regimen can be di⁄cult.Daily DOT
would be the ideal procedure resources permitting,
though frequent clinic visits coupled with home visits by
70 RESPIRATORYMEDICINEtheTB specialist nursemay su⁄ce.Monetaryor other in-
centivesmaybe necessary and transport costs shouldbe
met.One should not automatically assume poor compli-
ance in thosepatientswhoseproblems stem largely from
past inadequate prescribing.
For the non-compliant MDR-TB patient with a posi-
tive sputum, voluntary admission to an isolation unit
may be o¡ered but if this is refused, it may be necessary
to withdraw treatment initially to reduce the risk of de-
veloping further drug resistance. If all else fails, one may
be forced into making an application for a judicial court
order requiring con¢nement of the patient as a public
health hazard. In the U.K., these powers are limited and
apply only to patients of proven infectivity.
CONCLUSION
Knowledge that inadequate treatment can readily pro-
duce drug resistance dates back to the earliest days of
e¡ective chemotherapy. Health-care workers involved
in themanagement of TB in the U.K. should now be fully
aware of the prevalence of MDR-TB inmany other coun-
tries and should accordingly maintain the highest degree
of vigilance.The subject of MDR-TB is reviewed in more
detail elsewhere (23).
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